Beacon Therapeutics reported pivotal progress for laruparetigene zovaparvovec (laru-zova) in X-linked retinitis pigmentosa, describing a Phase 2/3 outcome that met the FDA-endorsed primary endpoint in the VISTA study. The company said improvement on low-luminance visual acuity favored both high- and low-dose cohorts, with responder proportions exceeding the untreated control group. The update strengthens the product’s path toward a biologics license application, as Beacon frames the result as a step closer to approval for a rare, vision-threatening condition. Investors will now focus on the durability of visual function gains and the evidence package required for labeling. Beacon’s readout arrives during a competitive gene therapy period for ocular indications, where manufacturing readiness and clinical consistency remain central to regulatory review.